Literature DB >> 25664197

Prevention of pelvic radiation disease.

Lorenzo Fuccio1, Leonardo Frazzoni1, Alessandra Guido1.   

Abstract

Pelvic cancers are among the most frequently diagnosed cancers worldwide. Treatment of patients requires a multidisciplinary approach that frequently includes radiotherapy. Gastrointestinal (GI) radiation-induced toxicity is a major complication and the transient or long-term problems, ranging from mild to very severe, arising in non-cancerous tissues resulting from radiation treatment to a tumor of pelvic origin, are actually called as pelvic radiation disease. The incidence of pelvic radiation disease changes according to the radiation technique, the length of follow up, the assessment method, the type and stage of cancer and several other variables. Notably, even with the most recent radiation techniques, i.e., intensity-modulated radiotherapy, the incidence of radiation-induced GI side effects is overall reduced but still not negligible. In addition, radiation-induced GI side effects can develop even after several decades; therefore, the improvement of patient life expectancy will unavoidably increase the risk of developing radiation-induced complications. Once developed, the management of pelvic radiation disease may be challenging. Therefore, the prevention of radiation-induced toxicity represents a reasonable way to avoid a dramatic drop of the quality of life of these patients. In the current manuscript we provide an updated and practical review on the best available evidences in the field of the prevention of pelvic radiation disease.

Entities:  

Keywords:  Amifostine; Aminosalicylates; Beclomethasone dipropionate; Gastrointestinal toxicity; Mesalazine; Misoprostol; Pelvic radiation disease; Probiotics supplementation; Radiotherapy; Sucralfate

Year:  2015        PMID: 25664197      PMCID: PMC4318744          DOI: 10.4292/wjgpt.v6.i1.1

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  49 in total

1.  Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.

Authors:  Vassilis E Kouloulias; John R Kouvaris; George Pissakas; Elias Mallas; Christos Antypas; John D Kokakis; George Matsopoulos; Spyros Michopoulos; Kyriaki Mystakidou; Lambros J Vlahos
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-01       Impact factor: 7.038

2.  Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.

Authors:  Anurag K Singh; Cynthia Ménard; Peter Guion; Nicole L Simone; Sharon Smith; Nancy Sears Crouse; Denise J Godette; Theresa Cooley-Zgela; Linda C Sciuto; Jonathan Coleman; Peter Pinto; Paul S Albert; Kevin Camphausen; C Norman Coleman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-26       Impact factor: 7.038

3.  Use of probiotics for prevention of radiation-induced diarrhea.

Authors:  P Delia; G Sansotta; V Donato; P Frosina; G Messina; C De Renzis; G Famularo
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 4.  Radiation protection in vivo by prostaglandins and related compounds of the arachidonic acid cascade.

Authors:  W R Hanson; K A Houseman; P W Collins
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

5.  Faecal incontinence: A late side-effect of pelvic radiotherapy.

Authors:  S Putta; H J N Andreyev
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-09       Impact factor: 4.126

6.  Sucralfate does not ameliorate acute radiation proctitis: randomised study and meta-analysis.

Authors:  N Hovdenak; H Sørbye; O Dahl
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-09       Impact factor: 4.126

7.  Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.

Authors:  Christopher D Jahraus; Doug Bettenhausen; Uzma Malik; Marguerite Sellitti; William H St Clair
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-15       Impact factor: 7.038

8.  Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, placebo-controlled study when treating localized pelvic cancer.

Authors:  R Henriksson; L Franzén; B Littbrand
Journal:  Am J Med       Date:  1991-08-08       Impact factor: 4.965

9.  A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis.

Authors:  C A Baughan; P A Canney; R B Buchanan; R M Pickering
Journal:  Clin Oncol (R Coll Radiol)       Date:  1993       Impact factor: 4.126

Review 10.  The radiotherapeutic injury--a complex 'wound'.

Authors:  James W Denham; Martin Hauer-Jensen
Journal:  Radiother Oncol       Date:  2002-05       Impact factor: 6.280

View more
  10 in total

Review 1.  Radiotherapy side effects: integrating a survivorship clinical lens to better serve patients.

Authors:  V Dilalla; G Chaput; T Williams; K Sultanem
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

2.  Predictive Factors of Late-onset Rectal Mucosal Changes After Radiotherapy of Prostate Cancer.

Authors:  Edy Ippolito; Alessandra Guido; Gabriella Macchia; Francesco Deodato; Lucia Giaccherini; Andrea Farioli; Alessandra Arcelli; Dajana Cuicchi; Leonardo Frazzoni; Savino Cilla; Milly Buwenge; Giovanna Mantini; Anna R Alitto; Marianna Nuzzo; Vincenzo Valentini; Marcello Ingrosso; Alessio G Morganti; Lorenzo Fuccio
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

Review 3.  Pelvic radiation disease: Updates on treatment options.

Authors:  Leonardo Frazzoni; Marina La Marca; Alessandra Guido; Alessio Giuseppe Morganti; Franco Bazzoli; Lorenzo Fuccio
Journal:  World J Clin Oncol       Date:  2015-12-10

4.  Stromal Progenitor Cells in Mitigation of Non-Hematopoietic Radiation Injuries.

Authors:  Shilpa Kulkarni; Timothy C Wang; Chandan Guha
Journal:  Curr Pathobiol Rep       Date:  2016-09-07

Review 5.  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.

Authors:  Theresa A Lawrie; John T Green; Mark Beresford; Linda Wedlake; Sorrel Burden; Susan E Davidson; Simon Lal; Caroline C Henson; H Jervoise N Andreyev
Journal:  Cochrane Database Syst Rev       Date:  2018-01-23

6.  Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study.

Authors:  Aiping Wang; Zongxin Ling; Zhixiang Yang; Pawel R Kiela; Tao Wang; Cheng Wang; Le Cao; Fang Geng; Mingqiang Shen; Xinze Ran; Yongping Su; Tianmin Cheng; Junping Wang
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

7.  Radiofrequency ablation in a patient with radiation enteritis: A case report.

Authors:  Xing-Jie Shen; Liang Liu; Jing-Yu Zhu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

8.  The Effects of Hyperbaric Oxygen Therapy on Pelvic Radiation Induced Gastrointestinal Complications (Rectal Bleeding, Diarrhea, and Pain): A Meta-Analysis.

Authors:  Jun-Hua Yuan; Li-Min Song; Yuan Liu; Man-Wen Li; Qian Lin; Rui Wang; Cai-Shun Zhang; Jing Dong
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

Review 9.  Update on the management of the gastrointestinal effects of radiation.

Authors:  Hannah McCaughan; Stephen Boyle; John J McGoran
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 10.  Clinical utility of hyperbaric oxygen therapy in genitourinary medicine.

Authors:  Jason Gandhi; Omar Seyam; Noel L Smith; Gunjan Joshi; Sohrab Vatsia; Sardar Ali Khan
Journal:  Med Gas Res       Date:  2018-04-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.